Vanguard Group’s Repros Therapeutics Inc. RPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q1 | – | Sell |
-735,447
| Closed | -$486K | – | 4163 |
|
|
2017
Q4 | $486K | Sell |
735,447
-66,290
| -8% | -$33.5K | ﹤0.01% | 3755 |
|
|
2017
Q3 | $256K | Buy |
801,737
+7,434
| +0.9% | +$2.61K | ﹤0.01% | 3873 |
|
|
2017
Q2 | $366K | Sell |
794,303
-95,547
| -11% | -$69.4K | ﹤0.01% | 3782 |
|
|
2017
Q1 | $1.07M | Buy |
889,850
+7,414
| +0.8% | +$9.27K | ﹤0.01% | 3560 |
|
|
2016
Q4 | $1.17M | Sell |
882,436
-76,541
| -8% | -$133K | ﹤0.01% | 3514 |
|
|
2016
Q3 | $2M | Sell |
958,977
-45,064
| -4% | -$89.1K | ﹤0.01% | 3394 |
|
|
2016
Q2 | $1.62M | Buy |
1,004,041
+174,610
| +21% | +$335K | ﹤0.01% | 3448 |
|
|
2016
Q1 | $805K | Buy |
829,431
+2,241
| +0.3% | +$2.19K | ﹤0.01% | 3657 |
|
|
2015
Q4 | $1M | Buy |
827,190
+64,352
| +8% | +$207K | ﹤0.01% | 3631 |
|
|
2015
Q3 | $5.67M | Buy |
762,838
+59,551
| +8% | +$455K | ﹤0.01% | 2909 |
|
|
2015
Q2 | $5.03M | Sell |
703,287
-3,620
| -0.5% | -$28.2K | ﹤0.01% | 3020 |
|
|
2015
Q1 | $6.07M | Buy |
706,907
+56,682
| +9% | +$507K | ﹤0.01% | 2900 |
|
|
2014
Q4 | $6.48M | Sell |
650,225
-7,635
| -1% | -$65.1K | ﹤0.01% | 2756 |
|
|
2014
Q3 | $6.51M | Buy |
657,860
+16,477
| +3% | +$244K | ﹤0.01% | 2700 |
|
|
2014
Q2 | $11.1M | Buy |
641,383
+32,249
| +5% | +$526K | ﹤0.01% | 2463 |
|
|
2014
Q1 | $10.8M | Buy |
609,134
+39,371
| +7% | +$762K | ﹤0.01% | 2452 |
|
|
2013
Q4 | $10.4M | Buy |
569,763
+20,805
| +4% | +$393K | ﹤0.01% | 2440 |
|
|
2013
Q3 | $14.7M | Buy |
548,958
+28,300
| +5% | +$606K | ﹤0.01% | 2223 |
|
|
2013
Q2 | $9.61M | Buy |
+520,658
| New | +$9.19M | ﹤0.01% | 2346 |
|
Vanguard Group's RPRX Position: Q1 2018 in Review
Vanguard Group sold out of Repros Therapeutics Inc. (RPRX) in Q1 2018, closing a stake of 735,447 shares — an estimated $486K sold.
Vanguard Group first reported a position in RPRX in Q2 2013 and held it in 19 quarters. The position peaked at $14.7M in Q3 2013. 1 fund tracked by Wall St. Rank holds RPRX as of Q1 2018.
- Vanguard Group reported no remaining Repros Therapeutics Inc. position as of Q1 2018 after selling out during the quarter.
- Vanguard Group sold 735,447 Repros Therapeutics Inc. shares in Q1 2018, an estimated $486K.
- Vanguard Group first reported a position in Repros Therapeutics Inc. in Q2 2013 and held it in 19 quarters.
- Vanguard Group's Repros Therapeutics Inc. position peaked at $14.7M in Q3 2013.
- 1 fund tracked by Wall St. Rank held Repros Therapeutics Inc. as of Q1 2018.
Based on Vanguard Group's 13F filing for Q1 2018, filed 15 May 2018.